EMJ Hematology最新文献_第7页

β-Thalassaemias: Highlights from the European Hematology Association Scientific Working Group (EHA-SWG) Scientific Meeting on Anaemias: Diagnosis and Treatment in the Omics Era β-地中海贫血:来自欧洲血液学协会科学工作组(EHA-SWG)贫血科学会议的亮点:组学时代的诊断和治疗

EMJ Hematology Pub Date : 2017-09-22 DOI: 10.33590/emjhematol/10314834

Kate L. Weatherall

引用次数: 0

Different Therapeutic Interventions and Mechanisms of Action of Antisickling Agents Currently in Use in Sickle Cell Disease Management 目前在镰状细胞病治疗中使用的抗镰状细胞药物的不同治疗干预措施和作用机制

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10310189

N. Imaga, O. Taiwo

{"title":"Different Therapeutic Interventions and Mechanisms of Action of Antisickling Agents Currently in Use in Sickle Cell Disease Management","authors":"N. Imaga, O. Taiwo","doi":"10.33590/emjhematol/10310189","DOIUrl":"https://doi.org/10.33590/emjhematol/10310189","url":null,"abstract":"Sickle cell disease is a genetic disorder caused by sickle haemoglobin. In many forms of the disease, the red blood cells can change shape upon deoxygenation due to abnormal sickle haemoglobin polymerisation. The haemoglobin proteins stick to each other, causing the cell to have a rigid surface and sickle shape and in the process damaging the red blood cell membrane, causing the cells to become stuck in blood vessels. This deprives the downstream tissues of oxygen and causes ischaemia and infarction (which may cause organ damage), such as stroke. Incidences of the disease are found most commonly in people of African descent and less commonly in people of Mediterranean, Latino, East Indian, and Arab descent (in that order). In African countries such as Nigeria, Gabon, Ghana, and the Republic of Congo, the prevalence of the sickle cell trait is between 20% and 30%, with the disease affecting ˜2–3% of the population. Herbal formulations prepared from plants are known as phytomedicines and are effective in keeping the patient out of a crisis state and enabling them to live stable lives in society, even though the faulty S gene is not eradicated but instead managed. This review highlights some of the therapeutic options in use in the management of sickle cell disease with a view to inspiring future research on this subject.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129743581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Thrombocytopenia: A Defect in Actin Dynamics? 血小板减少症:肌动蛋白动力学缺陷?

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10314114

A. Standing

引用次数: 3

The Role of Allograft in Acute Lymphoblastic Leukaemia, Including Alternate Donors 同种异体移植物在急性淋巴细胞白血病中的作用，包括替代供体

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10313027

J. Cooney

{"title":"The Role of Allograft in Acute Lymphoblastic Leukaemia, Including Alternate Donors","authors":"J. Cooney","doi":"10.33590/emjhematol/10313027","DOIUrl":"https://doi.org/10.33590/emjhematol/10313027","url":null,"abstract":"The management of acute lymphoblastic leukaemia (ALL) remains challenging. The changing landscape of newer agents and combinations of chemotherapy are improving outcomes, and various conditioning regimens and possible donor sources for allogeneic transplant provide management options; allograft remains the most potent anti-leukaemia therapy available. With improvements in treatments and monitoring of disease response, allogeneic transplantation is becoming more refined as an important option for selective patients with difficult disease. Although the paediatric ALL protocols used for adolescents and young adults are now extended towards the middle-aged patients, and newer therapeutic agents may be incorporated, there is evolving data comparing short and long-term outcomes and deliverability of treatment. Reliance on registry transplant data is inadequate in guiding optimal therapy for the individual, who may have a variety of specific needs. With the limited clinical trials in this field, it is important to continue reviewing progress and outcomes with alternative stem cell sources, such as mismatched unrelated donors, haploidentical donors, and cord blood transplants, which may cure many patients, though carry risks of treatment-related mortality and morbidity. Conditioning regimens of reduced toxicity have enabled the older and higher risk patients to proceed to allograft, but it remains hazardous. It is important to understand the features of the malignant cells, response to therapies, individual patient factors, donor stem cells available, and patient’s wishes, to help craft the current management. Allogeneic transplantation remains a very important option for ALL, and patient selection and path to transplant are continuing to evolve and be guided by ongoing clinical and laboratory data, including minimal residual disease assessment.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117288866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Double-Hit and Triple-Hit Lymphomas: New Perspectives for Their Classification 双重打击和三重打击淋巴瘤:分类的新视角

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10313900

Cristiano Claudino Oliveira, Maria Aparecida Custódio Domingues

引用次数: 1

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10314409

E. Skinner

引用次数: 0

Improving Treatment Strategies for Patients with Follicular Lymphoma: How to Translate Novel Study Data into Clinical Practice 改进滤泡性淋巴瘤患者的治疗策略:如何将新的研究数据转化为临床实践

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10311418

Blair R. Hesp

引用次数: 0

Patients in Focus: What’s Relevant for Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia? 焦点患者:慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的相关性?

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10312026

S. Etheridge

引用次数: 0

The Role and Regulation of Quiescence in Acute Lymphoblastic Leukaemia 静止在急性淋巴细胞白血病中的作用和调控

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10311523

Robin L Williams, Peter M. Gordon

{"title":"The Role and Regulation of Quiescence in Acute Lymphoblastic Leukaemia","authors":"Robin L Williams, Peter M. Gordon","doi":"10.33590/emjhematol/10311523","DOIUrl":"https://doi.org/10.33590/emjhematol/10311523","url":null,"abstract":"There are ˜3,000 children, as well an additional ˜7,000 adults, diagnosed with acute lymphoblastic leukaemia (ALL) each year in the USA. This makes ALL the most common cancer diagnosed in children. It represents ˜25% of paediatric cancer diagnoses. With current therapy, most patients achieve a complete remission and many are cured. However, the prognosis remains quite poor for the ˜15–20% of children who suffer a relapse of their ALL. Improved outcomes for these relapsed patients will require either more efficacious salvage therapies or improved initial therapy that prevents ALL relapse. Thus, understanding the mechanisms by which a small population of leukaemia cells can escape therapy and contribute to relapse often months or years later is critical for improving ALL outcomes. Herein, we will review emerging clinical and laboratory research that suggest quiescence, or dormancy, is an important cellular mechanism that enhances ALL chemo-resistance and persistence, and ultimately contributes to disease relapse. Furthermore, the mechanisms that regulate this balance between leukaemia quiescence and proliferation are beginning to be elucidated and will provide new knowledge about leukaemia biology. Finally, these observations support the need for and feasibility of therapeutically targeting these quiescent, chemo-resistant ALL cells by either exploiting metabolic or signalling pathway vulnerabilities unique to quiescent cells, or by causing the release of ALL cells from the protective niche(s) that triggers and maintains ALL quiescence.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122187818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shifting Treatment Paradigms in Non-Hodgkin Lymphomas 非霍奇金淋巴瘤治疗模式的转变

EMJ Hematology Pub Date : 2017-08-08 DOI: 10.33590/emjhematol/10310138

Nicole Rossides

引用次数: 0